Our Mission

To accelerate oligonucleotide therapies to the clinic with scalable, high-purity and sustainable processes - setting new drug standards from concept to care.

Current manufacturing processes are unsustainable for future demand:

>4300 kg of waste used per kg of RNA

Conventional purification is inconsistent and struggles with long or heavily modified RNA

High manufacturing costs exceed those of conventional drugs, limiting accessibility

Pre-clinical processes fail to translate to clinical production - driving CMC & performance variability

GemBio is transforming oligonucleotide production with a scalable, high-purity, and sustainable manufacturing platform to meet growing demand for both approved and future oligonucleotide therapeutics.

Our proprietary purification and manufacturing technology ensures consistent, commercial-grade oligonucleotides from research to clinical production, eliminating CMC variability. By improving efficiency and reducing manufacturing costs, GemBio will set new industry standards, empowering partners to deliver breakthrough therapies to patients with greater speed and reliability.